TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01952470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa
Description: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline.
Description: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Study: NCT02059005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Community Disease Management
Description: Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
Study: NCT02561624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change communication via text message
Study: NCT01594385

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seprafilm
Description: Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~* Two Seprafilm pieces between the liver and the anterior abdominal wall~* Four pieces over the exposed bowel surfaces anteriorly~* Two slightly staggered pieces of Seprafilm in each colic gutter~* Two pieces in the pelvic area.~* If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair.
Study: NCT02276573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: buccal cavity sample
Study: NCT04071587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface training
Description: Training with RecoveriX system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard physiotherapy and occupational therapy according to clinical routines.
Study: NCT00867477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breathing Test
Description: Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breathing Test
Description: Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Symptoms Questionnaire
Description: 3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Symptoms Questionnaire
Description: 3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pet Scan
Description: Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
Study: NCT01764802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: behavioral, psychological or informational intervention
Description: Participate in enhanced standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavioral, psychological or informational intervention
Description: Participate in psychological intervention
Study: NCT02734433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Study: NCT01683773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: Intramuscular needle injection 1x10\^11 vp
Study: NCT03163160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor manual therapy group
Description: Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor electrolysis group
Description: An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks.
Study: NCT01559727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
Study: NCT00281944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00258687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: 4 vaccines every two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: 4 vaccines every two weeks
Study: NCT00690495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol (drug), intravenous, induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1%
Description: Propofol (drug), intravenous, induction of anesthesia
Study: NCT00281944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo PET/CT scan
Study: NCT02303743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Phone Application
Description: Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
Study: NCT01361633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: single oral administration of 250 mg d-cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Single oral administration 250 mg Sugar Pill
Study: NCT00558402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: meditation class 1/week for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respite only
Description: Respite care 90 mins per week for 8 weeks
Study: NCT02303743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Written instructions with visual aids
Description: written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
Study: NCT01839643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 2.4 g
Description: 2.4 g in Vaginal Ring
Study: NCT02355509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills are given instead of acarbose in this group
Study: NCT01839643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 3.0 g
Description: 3.0 g in Vaginal Ring
Study: NCT04871373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: A periodontist was trained and evaluated by two expert psychologists in MI, who also supervised the interviewer to ensure that the intervention was properly applied. The periodontist conducted sessions of motivational interviewing monthly to the participants of the experimental group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene Instructions
Description: A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Instructions
Description: A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.
Study: NCT02093143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
Study: NCT00048854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
Study: NCT00069953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients \>70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
Study: NCT00048854

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
Study: NCT04161885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous (SC) or intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous (SC) or intravenous (IV) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
Study: NCT03194776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LLG783
Description: LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
Study: NCT02492061

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Demand creation for couples' HCT
Description: The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
Study: NCT00290082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loxapine, midazolam
Description: agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loxapine, midazolam
Description: agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: was evaluated in patients sedated, alcohol level, blood sugar

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: was evaluated in patients sedated, alcohol level, blood sugar

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient monitoring
Description: Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient monitoring
Description: Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxapine
Description: Loxapine 1 mL / 10 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 1 mL / 10 Kg
Study: NCT00069953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
Study: NCT02851043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneuRIP (breathing with resistance)
Description: subjects are given a resistance element to breath through

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respitrace system (Carefusion) (breathing without resistance)
Description: subjects are asked to breath normally
Study: NCT01648218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral protamine hagedorn (NPH) insulin
Study: NCT01903239

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Low-Risk BCC Excisional Margins
Description: After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
Study: NCT00069953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
Study: NCT01648218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular human insulin or Insulin Aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Study: NCT00069953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
Study: NCT06264193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: The athletes were living in hypoxic rooms, and training was carried out on lowlands.
Study: NCT03289962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene cevumeran
Description: Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
Study: NCT05900453

Intervention type: OTHER
Intervention: Clinical decision support (CDS) tool
Description: The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making.
Study: NCT03676036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107E

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT01632358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP311 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01442974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus nab-paclitaxel
Description: Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
Study: NCT00591357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loperamide
Description: 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
Study: NCT00530179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Blood Stem Transplantation
Description: 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: 6 - 21 DAY Cycles of R-CHOP
Study: NCT02846662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONEMO
Description: The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
Study: NCT02887950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Equikilon-3 months
Description: The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Equikilon-6 months
Description: The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.